Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Guardant Health's annualizedGross Profit for the quarter that ended in Dec. 2023 was $370.1 Mil.
Guardant Health's average Total Assets over the quarter that ended in Dec. 2023 was $1,791.8 Mil. Therefore, Guardant Health's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 20.66%.
Guardant Health Gross-Profit-to-Asset % Historical Data
The historical data trend for Guardant Health's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Guardant Health's Gross-Profit-to-Asset %
For the Diagnostics & Research subindustry, Guardant Health's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Guardant Health's Gross-Profit-to-Asset % falls into.
Guardant Health Gross-Profit-to-Asset % Calculation
Guardant Health's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Guardant Health Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Guardant Health's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health (Guardant Health) Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 